1-800-567-8911 or
604-682-5050
(Telephone interpreting in over 150 languages available)
Galcanezumab
Trade Name:
Emgality
Manufacturer/Distributor:
Eli Lilly Canada
Classification:
CGRP binding antibody
Migraine prevention therapy
ATC Class:
N02CD02 - galcanezumab
Status:
active
Notice of Compliance (yyyy/mm/dd):
2019/07/30
Date Marketed in Canada (yyyy/mm/dd):
2019/10/02
Presentation:
Injection: 120 mg/mL. DIN: 02491087
Comments:
Monthly injection for prevention of migraine in adults who have 4 or more migraines per month.
Back to:
Drug Product Listings 
